Payment overview · 2025
General Payments
$875.14
48 reported records · 14 companies
Healthcare provider profile · identity verified
David William Carlson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GARLAND, TX · NPI 1700961406
Verified facts
What the public records show
CMS Open Payments records show David William Carlson, M.D. received $875.14 in general payments during 2025 across 48 reported records.
Lilly USA, LLC accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $226.43 | 25.9% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.74 | 16.5% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.93 | 10.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $86.07 | 9.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $73.79 | 8.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.22 | 4.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.16 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.59 | 3.6% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $28.21 | 3.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.01 | 3.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $27.87 | 3.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.51 | 3.1% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.46 | 2.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.15 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $875.14 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $165.50 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $165.50 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.35 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $90.93 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $90.93 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $90.93 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $86.07 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $73.79 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $51.76 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.01 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $9.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 697 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 203 |
| Alprazolam | Alprazolam | 508 | 89 |
| Tramadol Hcl | Tramadol Hcl | 490 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 450 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 141 |
| Lisinopril | Lisinopril | 346 | 163 |
| Losartan Potassium | Losartan Potassium | 329 | 149 |
| Metformin Hcl | Metformin Hcl | 276 | 113 |
| Potassium Chloride | Potassium Chloride | 260 | 128 |
| Glimepiride | Glimepiride | 258 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 99 |
| Zolpidem Tartrate | Zolpidem Tartrate | 238 | 48 |
| Ezetimibe | Ezetimibe | 231 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 94 |
| Furosemide | Furosemide | 187 | 90 |
| Omeprazole | Omeprazole | 184 | 81 |
| Gabapentin | Gabapentin | 173 | 77 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 128 | 52 |
| Trazodone Hcl | Trazodone Hcl | 127 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 73 |
| Diazepam | Diazepam | 112 | 22 |
| Clonazepam | Clonazepam | 109 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 39 |
| Montelukast Sodium | Montelukast Sodium | 103 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 44 |
| Eliquis | Apixaban | 100 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 42 |
| Lorazepam | Lorazepam | 91 | 14 |
| Carvedilol | Carvedilol | 89 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 35 |
| Meloxicam | Meloxicam | 88 | 47 |
| Pregabalin | Pregabalin | 84 | 19 |
| Alendronate Sodium | Alendronate Sodium | 83 | 34 |
| Simvastatin | Simvastatin | 83 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 31 |
| Mounjaro | Tirzepatide | 71 | 19 |
| Sertraline Hcl | Sertraline Hcl | 69 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 36 |
| Allopurinol | Allopurinol | 64 | 25 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 64 | 16 |
| Donepezil Hcl | Donepezil Hcl | 64 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 42 |
| Temazepam | Temazepam | 61 | 11 |
| Levofloxacin | Levofloxacin | 57 | 51 |
| Metformin Hcl Er | Metformin Hcl | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 23 |
| Azithromycin | Azithromycin | 50 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 29 |
| Benazepril Hcl | Benazepril Hcl | 48 | 19 |
| Fluconazole | Fluconazole | 47 | 37 |
| Solifenacin Succinate | Solifenacin Succinate | 45 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 22 |
| Bupropion Xl | Bupropion Hcl | 41 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 20 |
| Telmisartan | Telmisartan | 41 | 16 |
| Trulicity | Dulaglutide | 41 | 17 |
| Buspirone Hcl | Buspirone Hcl | 40 | 20 |
| Clonidine Hcl | Clonidine Hcl | 40 | 19 |
| Glipizide | Glipizide | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | 15 |
| Methylprednisolone | Methylprednisolone | 39 | 38 |
| Etodolac | Etodolac | 38 | 18 |
| Jardiance | Empagliflozin | 36 | 20 |
| Naproxen | Naproxen | 36 | 20 |
| Ondansetron Odt | Ondansetron | 36 | 21 |
| Prednisone | Prednisone | 36 | 32 |
| Cefdinir | Cefdinir | 35 | 33 |
| Valsartan | Valsartan | 35 | 13 |
| Belsomra | Suvorexant | 34 | 16 |
| Ibuprofen | Ibuprofen | 34 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Atenolol | Atenolol | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 33 | 19 |
| Finasteride | Finasteride | 32 | 14 |
| Nifedipine Er | Nifedipine | 32 | 15 |
| Januvia | Sitagliptin Phosphate | 31 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 14 |
| Terazosin Hcl | Terazosin Hcl | 29 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | 11 |
| Famotidine | Famotidine | 25 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 16 |
| Lidocaine | Lidocaine | 25 | 12 |
| Oxazepam | Oxazepam | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 15 |
| Mupirocin | Mupirocin | 24 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 16 |
| Risperidone | Risperidone | 23 | 11 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 12 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 11 |
| Ozempic | Semaglutide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $875.14 · 48 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, BREZTRI, COMIRNATY, FREESTYLE LIBRE 3, General - Therapies, JARDIANCE, KISUNLA, Korlym, LOREEV XR, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Senza, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error